Advancements in Ultrasound Imaging for Assessing the biological behavior of Hepatocellular Carcinoma

Di Shi; Li Li

doi:10.54097/geg0bx51

Authors

Di Shi
Li Li

DOI:

https://doi.org/10.54097/geg0bx51

Keywords:

Contrast-enhanced Ultrasound, Hepatocellular Carcinoma, Biological Behavior

Abstract

Since the advent of contrast-enhanced ultrasound technology in 1968, with the continuous innovation of contrast agents, the increasing refinement of the resolution of ultrasound equipment, and the vigorous development of new imaging technologies, this technology has gradually demonstrated its irreplaceable unique advantages in many fields such as the diagnosis, treatment, and efficacy evaluation of hepatocellular carcinoma (HCC). It can not only provide more accurate medical imaging support, but also is expected to reveal more biological characteristics of HCC, providing a solid basis for personalized treatment decisions in the era of precision medicine.

Downloads

Download data is not yet available.

References

[1] Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma [J]. Expert Review of Gastroenterology & Hepatology, 2021, 15(11): 1295-1307.

[2] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the global burden of disease study 2017[J]. The Lancet, 2019, 394(10204): 1145-1158.

[3] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet (London, England), 2018, 391(10127): 1301-1314.

[4] Karadag Soylu N. Update on hepatocellular carcinoma: A brief review from pathologist standpoint[J]. Journal of Gastrointestinal Cancer, 2020, 51(4): 1176-1186.

[5] Imura S, Teraoku H, Yoshikawa M, et al. Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the milan criteria[J]. International Journal of Clinical Oncology, 2018, 23(1): 98-103.

[6] Zhang D, Zhang X Y, Lu W W, et al. Predicting ki-67 expression in hepatocellular carcinoma: Nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures[J]. Abdominal Radiology, 2024, 49(5): 1419-1431.

[7] Quaglia A. Hepatocellular carcinoma: A review of diagnostic challenges for the pathologist[J]. Journal of Hepatocellular Carcinoma, 2018, 5: 99-108.

[8] Moribata K, Tamai H, Shingaki N, et al. Assessment of malignant potential of small hypervascular hepatocellular carcinoma using B-mode ultrasonography[J]. Hepatology Research: The Official Journal of the Japan Society of Hepatology, 2011, 41(3): 233-239.

[9] Lim C, Mise Y, Sakamoto Y, et al. Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J]. World Journal of Surgery, 2014, 38(11): 1.

[10] Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. The New England Journal of Medicine, 2008, 359(4): 378-390.

[11] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.

[12] Wei Y, Lv D. Correlation of N-ras gene expression in hepatocellular carcinoma with color doppler ultrasound findings [J]. Journal of Biomaterials and Tissue Engineering, 2021, 11(10): 1996-2000.

[13] Yihuan W, Ruokun L, Huanhuan C, et al. Research progress of gd-EOB-DTPA-enhanced magnetic resonance imaging in the evaluation of biological behavior of hepatocellular carcinoma [J]. JOURNAL OF SHANGHAI JIAO TONG UNIVERSITY, 2022.

[14] Han H, Ji Z, Ding H, et al. Assessment of blood flow in the hepatic tumors using non-contrast micro flow imaging: Initial experience[J]. Clinical Hemorheology and Microcirculation, 2019, 73(2): 307-316.

[15] Sawatzki M, Burkart T, Baumeler S, et al. Ultrasound doppler technique for the diagnosis of focal nodular hyperplasia - case series and systematic review[J]. Medical Ultrasonography, 2024, 26(1): 72-82.

[16] Han H, Ji Z, Ding H, et al. Assessment of blood flow in the hepatic tumors using non-contrast micro flow imaging: Initial experience[J]. Clinical Hemorheology and Microcirculation, 2019, 73(2): 307-316.

[17] Friedman S L. Mechanisms of hepatic fibrogenesis[J]. Gastroenterology, 2008, 134(6): 1655-1669.

[18] Yen Y H, Kee K M, Li W F, et al. Causes of death among patients with hepatocellular carcinoma according to chronic liver disease etiology[J]. Cancers, 2023, 15(6): 1687.

[19] European Association for the Study of the Liver, Clinical Practice Guideline Panel, Chair:, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update[J]. Journal of Hepatology, 2021, 75(3): 659-689.

[20] Kim S U, Ahn S H, Park J Y, et al. Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan((R))) before curative resection of hepatocellular carcinoma: A pilot study[J]. Hepatology International, 2008, 2(4): 471-477.

[21] Zhong X, Long H, Chen L, et al. Stiffness on shear wave elastography as a potential microenvironment biomarker for predicting tumor recurrence in HBV-related hepatocellular carcinoma[J]. Insights into Imaging, 2023, 14(1): 147.

[22] Nacheva-Georgieva E L, Doykov D I, Andonov V N, et al. Point shear wave elastography and 2-dimensional shear wave elastography as a non-invasive method in differentiating benign from malignant liver lesions[J]. Gastroenterology Insights, 2022, 13(3): 296-304.

[23] Jiang D, Qian Y, Gu Y J, et al. Predicting hepatocellular carcinoma: A new non-invasive model based on shear wave elastography[J]. World Journal of Gastroenterology, 2024, 30(25): 3166-3178.

[24] Huang Z, Zhou P, Li S, et al. Prediction of the ki-67 marker index in hepatocellular carcinoma based on dynamic contrast-enhanced ultrasonography with sonazoid[J]. Insights into Imaging, 2022, 13(1): 199.

[25] Tada T, Kumada T, Toyoda H, et al. Utility of contrast-enhanced ultrasonography with perflubutane for determining histologic grade in hepatocellular carcinoma[J]. Ultrasound in Medicine & Biology, 2015, 41(12): 3070-3078.

[26] Huang J Y, Li J W, Lu Q, et al. Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for hepatocellular carcinoma[J]. Radiology, 2020, 294(2): 329-339.

[27] Deng S, Jiang Q, Wang Y, et al. Relationship between quantitative contrast-enhanced ultrasonography parameters and angiogenesis in primary small hepatocellular carcinoma: A retrospective study[J]. Medicine, 2021, 100(27): e26489.

[28] Liu J Q, Ren J Y, Xu X L, et al. Ultrasound-based artificial intelligence in gastroenterology and hepatology[J]. World Journal of Gastroenterology, 2022, 28(38): 5530-5546.